Momat, 1 piece, 15 g, 0.1%, ointment for external use

Momat ointment for external use 0.1% 15g

Momat, 1 piece, 15 g, 0.1%, ointment for external use

Elokom cream, ointment, lotion are indicated only for dermatological use and are not intended for use in ophthalmology.

As a result of systemic absorption with local use of various glucocorticosteroid drugs, reversible suppression of the function of the hypothalamic-pituitary-adrenal system, as well as symptoms of glucocorticosteroid insufficiency after discontinuation of the drug, may occur. In patients, as a result of systemic absorption of glucocorticosteroids during systemic use, Cushing's syndrome, hyperglycemia and glycosuria may also develop.

Patients receiving topical corticosteroids for the treatment of large areas of skin or under occlusive dressings should be periodically monitored for signs of suppression of the hypothalamic-pituitary-adrenal axis. This can be done by performing an ACTH stimulation test, measuring morning cortisol in plasma and in media other than urine. If suppression of the hypothalamic-pituitary-adrenal system is noted, the interval between applications should be increased, or another less potent glucocorticosteroid should be used, or the drug should be discontinued. Restoration of the function of the hypothalamic-pituitary-adrenal system usually occurs soon after discontinuation of local glucocorticosteroids. Sometimes signs and symptoms of glucocorticosteroid deficiency may appear, which requires additional use of systemic glucocorticosteroids, a description of which can be found in the annotations for such drugs.

The drug Elokom can be used in children from 2 years of age, however, it should be borne in mind that the safety and effectiveness of its use in children for a period exceeding 3 weeks have not been studied.

Due to the fact that children have a larger surface area to body weight ratio than adults, children are at greater risk of suppressing the function of the hypothalamic-pituitary-adrenal axis and the occurrence of Cushing's syndrome when using any topical glucocorticosteroid drugs. For the same reason, children have a higher risk of adrenal insufficiency when treatment with topical glucocorticosteroids is discontinued. When treated with local glucocorticosteroids in children, atrophic changes in the skin occur more easily, up to the appearance of atrophic stripes. The risk of suppression of the hypothalamic-pituitary-adrenal system in children increases when glucocorticosteroids are applied to an area of ​​more than 20% of the body surface.

There are reports of suppression of the function of the hypothalamic-pituitary-adrenal system, the appearance of Cushing's syndrome, growth retardation, delayed weight gain and intracranial hypertension in children with topical use of various glucocorticosteroid drugs. Manifestations of adrenal insufficiency include low plasma cortisol and lack of response to ACTH stimulation. Intracranial hypertension leads to bulging fontanelles, headache, and bilateral papilledema.

Elokom ointment and cream should not be used to treat dermatitis caused by wearing diapers.

Ointment, cream and lotion should not be used under occlusive dressings unless prescribed by a doctor. Ointment and cream should not be applied to children on areas of skin that are under diapers or under waterproof underpants (occlusive dressing effect). The ointment and cream are not intended for use on the face or in the groin and armpit areas.

If irritation occurs, use of Elokom should be discontinued and appropriate treatment prescribed. Allergic contact dermatitis with corticosteroids is usually diagnosed by evidence of treatment failure, which should be confirmed by skin testing.

If a concomitant skin infection develops, an appropriate antifungal or antibacterial agent should be used. If a positive response to treatment is not achieved quickly, use of the drug should be suspended until the infection is eliminated.

As with other glucocorticosteroids, use of Elokom cream, ointment and lotion should be discontinued once cured. If there is no improvement within 2 weeks after starting therapy, the diagnosis may need to be clarified.

Momat

Momat (mometasone) is an artificially synthesized local glucocorticosteroid. Available in the form of cream and ointment. Relieves inflammation, eliminates itching, prevents exudation. Stimulates the formation of proteins that suppress the activity of acetylhydrolase, platelet activating factor and lipomodulins, which, in turn, are responsible for the synthesis of biologically active substances that provide chemical and molecular bonds in the site of inflammation and ensure the development of the inflammatory reaction - prostaglandins and leukotrienes. This occurs due to inhibition of the release of the latter's precursor, arachidonic acid. When applied externally, mometasone is only slightly absorbed into the systemic bloodstream (8 hours after its application to the skin, no more than 0.5% of the active substance penetrates into the blood). The drug undergoes intensive metabolic transformations by microsomal liver enzymes. Elimination from the body is carried out mainly by the kidneys and, to a lesser extent, by the intestines. Momat is indicated to eliminate itching and inflammation in dermatoses (dermatitis, eczema, etc.) that respond to the action of glucocorticosteroids. Momat is contraindicated in case of individual intolerance to mometasone, rosacea, dermatitis of the perioral area, bacterial, viral (herpes, chickenpox, shingles) or fungal skin lesions, reactions that occur after preventive or therapeutic vaccination, as well as during pregnancy and breastfeeding (in the latter In this case, this means long-term treatment or use of the drug in submaximal and maximum doses).

It is recommended to take special care when using Momat on the face or under an airtight bandage. Frequency of use – 1 time per day. The duration of pharmacotherapy is determined by the doctor depending on the effectiveness of the treatment, the patient’s tolerability of the drug, and the presence and severity of unwanted side reactions. With prolonged use of Momat, as well as other local glucocorticosteroids, the risk of developing systemic side effects increases (this is especially true for patients of younger age groups, as well as cases of using the drug under an airtight bandage). Given this fact, patients should be monitored to prevent the development of hypocortisolism syndrome and suppression of the hypothalamic-pituitary-adrenal system. As one of the auxiliary components, Momat contains propylene glycol, which can cause local allergic reactions. If the latter develop, the medication course should be suspended. It must be borne in mind that Momat, as well as other external glucocorticosteroids, can modify the clinical signs of some dermatological diseases, which makes their diagnosis difficult.